Related references
Note: Only part of the references are listed.Vardenafil in Pulmonary Arterial Hypertension A Randomized, Double-blind, Placebo-controlled Study
Zhi-Cheng Jing et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension
Robyn J. Barst et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2011)
Mechanisms of disease: pulmonary arterial hypertension
Ralph T. Schermuly et al.
NATURE REVIEWS CARDIOLOGY (2011)
Tadalafil for the treatment of pulmonary arterial hypertension
Erika B. Rosenzweig
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan
S. Faruqi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study
Dong Hyuk Kang et al.
KOREAN JOURNAL OF UROLOGY (2010)
Tadalafil Therapy for Pulmonary Arterial Hypertension
Nazzareno Galie et al.
CIRCULATION (2009)
Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension
Joanna Pepke-Zaba et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Guidelines for the diagnosis and treatment of pulmonary hypertension
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2009)
No Clinically Relevant Pharmacokinetic and Safety Interactions of Ambrisentan in Combination With Tadalafil in Healthy Volunteers
Rebecca Spence et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Diagnosis and Assessment of Pulmonary Arterial Hypertension
David B. Badesch et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Updated Clinical Classification of Pulmonary Hypertension
Gerald Simonneau et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Pulmonary hypertension
Gorev Grubu Uyeleri et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2009)
The cardiovascular safety of tadalafil
Thorsten Reffelmann et al.
EXPERT OPINION ON DRUG SAFETY (2008)
Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: A case series of 12 patients
Edgar Lik-Wui Tay et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2008)
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects
Rebecca E. Wrishko et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: A pilot study
Daniele Bendayan et al.
RESPIROLOGY (2008)
Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the α-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects
Michel Guillaume et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics
S. Thomas Forgue et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Pulmonary arterial hypertension in France - Results from a national registry
M Humbert et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval
CM Beasley et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells
B Tantini et al.
BASIC RESEARCH IN CARDIOLOGY (2005)
Survival with first-line bosentan in patients with primary pulmonary hypertension
VV McLaughlin et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction
M Gupta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Effect of tadalafil on cytochrome P450 3A4-mediated clearance: Studies in vitro and in vivo
BJ Ring et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
The endothelin system in pulmonary arterial hypertension
N Galié et al.
CARDIOVASCULAR RESEARCH (2004)
Tadalafil in primary pulmonary arterial hypertension
EA Palmieri et al.
ANNALS OF INTERNAL MEDICINE (2004)
Time course of the interaction between tadalafil and nitrates
RA Kloner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Overview of phosphodiesterase 5 inhibition in erectile dysfunction
RC Rosen et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension - Comparison with inhaled nitric oxide
E Michelakis et al.
CIRCULATION (2002)
ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells
N Davie et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Physiologic basis for the treatment of pulmonary hypertension
H Olschewski et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2001)
Genomic organization of the human phosphodiesterase PDE11A gene - Evolutionary relatedness with other PDEs containing GAF domains
K Yuasa et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Share Paper
